ArticleJournal of clinical microbiology2006
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003.
Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 3 syntheses or guidelines pooled it, 237 citations in OpenAlex.
- Clinical efficacy and safety of antifungal drugs for the treatment ofJournal of medical microbiology · 2021Pooled it
- Central venous catheter (CVC) removal for patients of all ages with candidaemia.The Cochrane database of systematic reviews · 2016Pooled it
- Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis.The Pediatric infectious disease journal · 2013Pooled it
- Evaluating the sensitivity of the Wako β-D-glucan assay for the diagnosis of candidemia caused by Candida parapsilosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Silent Persistence: Molecular Evidence of Clonal Transmission in Fluconazole-ResistantJournal of fungi (Basel, Switzerland) · 2025Article
- Good Outcomes After a Severity Triad: Systemic Complications, Bacterial and Fungal Infections in 3 Patients With Major Burns.Eplasty · 2025Article
- Clinical Characteristics of Candidemia Due toJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Combination of Systemic and Lock-Therapies with Micafungin Eradicate Catheter-Based Biofilms and Infections Caused byJournal of fungi (Basel, Switzerland) · 2024Article
- Candida parapsilosis complex in the clinical setting.Nature reviews. Microbiology · 2024Review
- [Fungal peritoneal dialysis catheter-related exit-site infection combined with tunnel infection: A case report].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023Article
- Clinical, Epidemiological and Laboratory Features of InvasiveJournal of fungi (Basel, Switzerland) · 2023Article
- Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap.The Lancet. Microbe · 2023Review
- InvasiveMicroorganisms · 2023Article
- Molecular Investigation of the Fatal BloodstreamInternational journal of molecular sciences · 2023Article
- Candidiasis and Other Emerging Yeasts.Current fungal infection reports · 2023Review
- Increase in the incidence ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- How to Identify Invasive Candidemia in ICU-A Narrative Review.Antibiotics (Basel, Switzerland) · 2022Review
- Global Prevalence of Antifungal-ResistantTropical medicine and infectious disease · 2022Review
- Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida parapsilosis has emerged as an important yeast species causing fungemia. We describe the incidence and epidemiology of C. parapsilosis fungemia. Data from active population-based surveillance in Barcelona, Spain, from January 2002 to December 2003 were analyzed. We focused on 78 episodes of C. parapsilosis fungemia, and we compared them with 175 Candida albicans controls. C. parapsilosis accounted for 23% of all fungemias. The annual incidences were 1 episode per 10(5) patients, 1.2 episodes per 10(4) discharges, and 1.7 episodes per 10(5) patient days. All isolates but one (99%) were fluconazole susceptible. Seventy-two isolates (92%) were inpatient candidemias. Forty-two episodes (51%) were considered catheter-related fungemia, 35 (45%) were considered primary fungemia, and 3 (4%) were considered secondary fungemia. Risk factors for candidemia were vascular catheterization (97%), prior antibiotic therapy (91%), parenteral nutrition (54%), prior surgery (46%), prior immunosuppressive therapy (38%), malignancy (27%), prior antifungal infection (26%), transplant recipient (16%), neutropenia (12%), and prior colonization (11%). Multivariate analysis of the differential characteristics showed that the factors that independently predicted the presence of C. parapsilosis fungemia were neonate patients (odds ratio [OR], 7.5; 95% confidence interval [CI], 2.1 to 26.8; P = 0.002), transplant recipients (OR, 9.2; 95% CI, 1.9 to 43.3; P = 0.005), patients with a history of prior antifungal therapy (OR, 5.4; 95% CI, 1.8 to 15.9; P = 0.002), and patients who received parenteral nutrition (OR, 2.2; 95% CI, 1.09 to 4.6; P = 0.028). The overall mortality rate was lower than that associated with C. albicans candidemia (23% versus 43%; P < 0.01). In summary, C. parapsilosis was responsible for 23% of all candidemias and was more frequent in neonates, in transplant recipients, and in patients who received parenteral nutrition or previous antifungal therapy, mainly fluconazole. The mortality rate was lower than that associated with C. albicans fungemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.